Dana-Farber Cancer Institute
New protein-targeting drug shows promise in early trial for patients with high-risk CLL
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
Cancer
May 17, 2013 |
not rated yet |
0
|
Scientists find mutation driving pediatric brain tumors
A type of low-grade but sometimes lethal brain tumor in children has been found in many cases to contain an unusual mutation that may help to classify, diagnose and guide the treatment of the tumors, report scientists at ...
Genetics
Apr 30, 2013 |
5 / 5 (1) |
0
|
Majority of children readmitted to hospital following stem cell transplant
Nearly two-thirds of children receiving stem cell transplants returned to the hospital within six months for treatment of unexplained fevers, infections or other problems, according to a study performed at Dana-Farber/Children's ...
Cancer
Apr 24, 2013 |
not rated yet |
0
Toxicity differences inform decision on conditioning for neuroblastoma transplants
MIAMI—The stem cell transplant regimen that was commonly used in the United States to treat advanced neuroblastoma in children appears to be more toxic than the equally effective regimen employed in Europe and Egypt, according ...
Cancer
Apr 24, 2013 |
not rated yet |
0
Delays in diagnosis worsen outlook for minority, uninsured pediatric retinoblastoma patients
When the eye cancer retinoblastoma is diagnosed in racial and ethnic minority children whose families don't have private health insurance, it often takes a more invasive, potentially life-threatening course than in other ...
Cancer
Apr 24, 2013 |
not rated yet |
1
